Primary giant cell carcinomas of the lung: a clinicopathological and immunohistochemical analysis of seven cases

Weissferdt, Annikka; Moran, César A.

doi:10.1111/his.12798

Cited by 19 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on characteristics such as early-stage metastasis and chemotherapy resistance, it is also important to detect molecular alterations that may improve drug efficacy and prolong patient survival. 89 Targeted therapy and immunotherapy are currently new research fields in PSC. Further in vivo and in vitro experiments are needed, as well as clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

Liu

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors. Because of its highly aggressive character and propensity for frequent metastasis, PSC shows low response rates to traditional treatments such as chemotherapy, radiotherapy, and neoadjuvant therapy. In recent years, considerable progress has been made in gene sequencing, targeted therapies, and immunotherapies. One of the most promising treatment approaches is the selection of mono-targeted or multi-targeted drugs according to tumor gene-mutation sites, such as epidermal growth factor receptor or vascular endothelial growth factor receptor 2 ( EGFR/VEGFR2), anaplastic lymphoma kinase ( ALK), and others. Another approach is the activation of therapeutic anti-tumor immunity via pathways including programmed cell-death protein-1/programmed cell-death ligand-1 ( PD-1/PD-L1), which has been used in individual cases. In this review, we will introduce the clinicopathologic features, molecular typing, and traditional treatments. We will also review the biological characteristics and the latest therapies for PSC. These novel therapies show promise in the management of PSC, and the outcomes of investigative trials will hopefully reveal a variety of treatment options for patients with PSC.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulmonary sarcomatoid carcinoma: progress, treatment and expectations

Liu

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…The hallmark of GCCL imaging often shows intrapulmonary masses with predominant involvement of the upper lobes of the lungs. [5,7–10] In this case, the patient presented with newborn parenchymal focal cyst in the left upper lobe. Cysts are described as thin-walled (<4 mm) air-containing spaces, while cavities are air-containing lesions with thick walls (≥5 mm).…”

Section: Discussionmentioning

confidence: 96%

“…[5] Patients with GCCLs have no specific signs or symptoms; the common complications of GCCLs include a cough, hemoptysis, chest pain, weight loss, dyspnea, and general malaise. [6,7] GCCLs can occur in any lobe of the lung, but are commonly found in the upper (52.7%) and lower lobes (21.7%). [5] The 5-year overall survival (OS) for patients with GCCLs is significantly less than that for patients with non-GCCL NSCLCs, probably because GCCL patients present with multiple adverse features, including a higher grade, larger tumor size, more advanced stage, and a tendency toward metastasis.…”

Section: Introductionmentioning

confidence: 99%

Giant cell carcinoma of the lung presenting as an isolated cyst containing air

Wang¹,

Liu²,

Qian³

et al. 2019

Medicine

View full text Add to dashboard Cite

Introduction: Pulmonary sarcomatoid carcinomas (PSCs) are rare tumors within the sarcomatoid carcinoma group. Giant cell carcinoma of the lung (GCCL) is a rare type of PSCs that consists entirely of highly pleomorphic tumor giant cells; the prognosis is poor. Patient concerns: A patient presented with a single cyst and was diagnosed with GCCL. The patient was a 59-year-old male who was admitted to the hospital with a cough. A chest computerized tomography (CT) scan showed a single, thin-walled cyst containing air in the left upper lobe of the lung. Bronchoscopy revealed chronic bronchitis. The initial diagnosis was pulmonary infection and the patient was treated with antibiotics. The cyst wall increased in thickness, and the cyst eventually formed a cavity. Diagnosis: Surgery was performed, and a diagnosis of GCCL was established. The stage was pT 1b N 1 M 0 (equal to stage IIB). Interventions: The patient underwent video-assisted thoracoscopic surgery and 4 cycles of adjuvant chemotherapy consisting of cisplatin and docetaxel. After 9 months, the patient occurred mediastinal lymph node metastasis, and received radiotherapy (60Gy/30F). Outcomes: His prognosis was good without progression (complete response) based on serial CT scans over 9 months of follow-up evaluations, then the patient occurred mediastinal lymph node metastasis. The patient lived during 30 months of follow-up, after which he was lost to follow-up. Conclusion: A solitary pulmonary parenchymal cystic lesion usually suggests an infectious disease or congenital abnormality; however, a cystic lesion is occasionally encountered in GCCL.

show abstract

“…By definition PLCa with a component of differentiated carcinoma will stain for cytokeratin. Negative or weak staining for CK is reported in a minority of GCCa while TTF1 and p40 are not expressed [14,15]. In a significant number of GCCa, HCG is expressed [3,15].…”

Section: Sarcomatoid Carcinoma Encompassing Spca Gcca and Plca -Morpmentioning

confidence: 99%

“…Negative or weak staining for CK is reported in a minority of GCCa while TTF1 and p40 are not expressed [14,15]. In a significant number of GCCa, HCG is expressed [3,15]. Given 4 the rarity of sarcomatoid carcinoma there is sparse data on their genetic background.…”

Section: Sarcomatoid Carcinoma Encompassing Spca Gcca and Plca -Morpmentioning

confidence: 99%